Financiado en parte por Amgen
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R, van Hout B
Clinical cardiology · 72 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Amgen
Según 1 financiador declarado.
Publicación
- Publicado
- 2016-04-19 · Clin Cardiol · vol. 39 · número 6 · págs. 313–320
- Editorial
- Wiley
- Citado
- 87 citas · más que el 100% de estudios similares · 17.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 38 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Health Systems, Economic Evaluations, Quality of Life · Coronary Interventions and Diagnostics
- Palabras clave
- evolocumab, LDL cholesterol lowering, cost-effectiveness, heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease, statin intolerance, PCSK9 inhibitors, quality-adjusted life years, cardiovascular risk, Markov model
- MeSH
- humans, cardiovascular diseases, recurrence, antibodies, monoclonal, anticholesteremic agents, treatment outcome, drug therapy, combination, models, economic, markov chains, risk factors, down-regulation, quality-adjusted life years, time factors, middle aged, cost-benefit analysis, drug costs, united states, female, male, dyslipidemias, cholesterol, ldl, randomized controlled trials as topic, clinical trials, phase iii as topic, antibodies, monoclonal, humanized, biomarkers
7 autores
- Shravanthi R. Gandra🇺🇸 · autor de correspondenciaAmgen (United States)
- Guillermo Villa🇨🇭Amgen (Switzerland)
- Gregg C. Fonarow🇺🇸University of California, Los Angeles
- Mickael Löthgren🇨🇭Amgen (Switzerland)
- Peter Lindgren🇸🇪Karolinska Institutet; Swedish Institute for Health Economics
- Ransi M. Somaratne🇺🇸Amgen (United States)
- Ben van Hout🇬🇧University of Sheffield
Resumen
El texto original del estudio, en el idioma en que se publicó.
Randomized trials have shown marked reductions in low-density lipoprotein cholesterol (LDL-C), a risk factor for cardiovascular disease (CVD), when evolocumab is administered. We hypothesized that evolocumab added to standard of care (SOC) vs SOC alone is cost-effective in the treatment of patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic CVD (ASCVD) with or without statin intolerance and LDL-C >100 mg/dL. Using a Markov cohort state transition model, primary and recurrent CVD event rates were predicted considering population-specific trial-based mean risk factors and calibrated against observed rates in the real world. The LDL-C-lowering effect from population-specific phase 3 randomized studies for evolocumab was used together with estimated LDL-C-lowering effect on CVD event rates per 38.67-mg/dL LDL-C lowering from a statin-trial meta-analysis. Costs and utilities were included from published sources. Evolocumab treatment was associated with both increased cost and improved quality-adjusted life-years (QALY): HeFH (incremental cost: US$153 289, incremental QALY: 2.02, incremental cost-effectiveness ratio: US$75 863/QALY); ASCVD (US$158 307, 1.12, US$141 699/QALY); and ASCVD with statin intolerance (US$136 903, 1.36, US$100 309/QALY). Evolocumab met both the American College of Cardiology/American Heart Association (ACC/AHA) and World Health Organization (WHO) thresholds in each population evaluated. Sensitivity and scenario analyses confirmed that model results were robust to changes in model parameters. Among patients with HeFH and ASCVD with or without statin intolerance, evolocumab added to SOC may provide a cost-effective treatment option for lowering LDL-C using ACC/AHA intermediate/high value and WHO cost-effectiveness thresholds. More definitive information on the clinical and economic value of evolocumab will be available from the forthcoming CVD outcomes study.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.